T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Advertisement
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Linperlisib will be investigated in a global registration study versus physician’s choice of standard treatment for R/R ...
Advertisement
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Based on promising results from the phase II TELLOMAK study, the FDA grants a breakthrough therapy designation for lacutamab.
Researchers have developed a new scoring system using one of the largest global cohorts of T-cell lymphoma patients.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Relmacabtagene autoleucel is an anti-CD19 chimeric antigen receptor T-cell product
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.